Sesame, America’s Low-Cost Leader in Healthcare, Is First Major Direct-to-Consumer Weight Loss Company to Offer Compounded Semaglutide to All 50 United States
16 oct. 2024 08h05 HE
|
Sesame
NEW YORK CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced that it has begun offering...
Americans Expected to Reduce Calorie Intake by Trillions as GLP-1 Usage Rises, According to New Study
09 oct. 2024 12h01 HE
|
Impact Analytics
New report from Impact Analytics reveals expected decline in calorie consumption across the US’s adult population by 2030
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03 oct. 2024 15h45 HE
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
$49.3 Bn GLP-1 Markets 2024-2035 with Boehringer Ingelheim, Eli Lilly, Novo Nordisk Dominating
01 oct. 2024 04h35 HE
|
Research and Markets
Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "GLP-1 Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type...
Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
08 août 2024 05h00 HE
|
Defiance ETFs
Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
High Use of Ozempic and Other Diabetes Drugs for Weight Loss Driving Down Clothing Sizes In New York City, According to New Study
17 juin 2024 07h00 HE
|
Impact Analytics
Impact Analytics announced that size small has become the most popular size for women on Manhattan’s Upper East Side.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
02 mai 2024 08h30 HE
|
Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01 mai 2024 09h00 HE
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Wholesale Weight Loss: Sesame Unveils Specialized Care for Weight Loss with Pricing Exclusively for Costco Members
02 avr. 2024 10h59 HE
|
Sesame
NEW YORK CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, today unveiled an...
Buoy Health Offers Effective Diabetic Care and Weight Management Solutions
20 mars 2024 21h00 HE
|
Buoy Health
Boston, MA , March 20, 2024 (GLOBE NEWSWIRE) -- Buoy Health, a cutting-edge digital healthcare platform committed to empowering people on their wellness journeys, is pleased to announce strategic...